Here are the S-1 registration statements from Adaptin Bio Inc (APTN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow APTN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTN filings page.
ADAPTIN BIO, INC. (APTN) has filed to register the resale of up to 382,400 shares of common stock held by selling stockholders and up to 38,240 shares issuable upon exercise of placement agent warrants. All resale proceeds go to the selling stockholders; Adaptin would receive cash only if the placement agent warrants are exercised.
The company is an early-stage biotechnology business developing its BRiTE (Brain Bispecific T‑cell Engager) platform to deliver therapeutics across the blood–brain barrier, with lead candidate APTN‑101 targeting EGFRVIII‑positive tumors such as glioblastoma. Common stock trades on the OTCQB under symbol APTN; on August 25, 2026, the last quoted price was $6.27 per share, with 9,244,937 shares outstanding.
Adaptin has generated no commercial revenue, has incurred recurring losses and negative operating cash flows, and its independent auditor has expressed substantial doubt about its ability to continue as a going concern. Management expects to require substantial additional capital, including in 2026, to fund clinical development and potential commercialization, and discloses extensive business, regulatory, manufacturing, financing and reimbursement risks associated with its drug-development programs.